Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) insider James Woodruff Lillie sold 22,082 shares of Maplight Therapeutics stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $12.54, for a total transaction of $276,908.28. Following the sale, the insider owned 202,380 shares in the company, valued at approximately $2,537,845.20. This trade represents a 9.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
James Woodruff Lillie also recently made the following trade(s):
- On Thursday, May 7th, James Woodruff Lillie sold 721 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.28, for a total transaction of $20,389.88.
- On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36.
Maplight Therapeutics Stock Up 3.1%
NASDAQ MPLT traded up $0.39 during trading on Tuesday, reaching $12.94. 847,553 shares of the company traded hands, compared to its average volume of 1,525,280. Maplight Therapeutics, Inc. has a 1-year low of $9.10 and a 1-year high of $40.43. The stock’s 50 day moving average price is $30.01 and its two-hundred day moving average price is $24.84.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in MPLT. Strs Ohio bought a new stake in Maplight Therapeutics during the 4th quarter worth about $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Maplight Therapeutics in the fourth quarter worth about $70,000. New York State Common Retirement Fund acquired a new position in shares of Maplight Therapeutics during the fourth quarter worth approximately $93,000. MetLife Investment Management LLC acquired a new position in shares of Maplight Therapeutics during the fourth quarter worth approximately $172,000. Finally, Walleye Capital LLC bought a new stake in shares of Maplight Therapeutics during the fourth quarter valued at approximately $205,000.
Analysts Set New Price Targets
MPLT has been the subject of a number of recent analyst reports. BMO Capital Markets initiated coverage on shares of Maplight Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $46.00 target price for the company. Jefferies Financial Group reaffirmed a “buy” rating on shares of Maplight Therapeutics in a research note on Monday, July 27th. Canaccord Genuity Group cut their target price on shares of Maplight Therapeutics from $43.00 to $24.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Craig Hallum reissued a “buy” rating and issued a $25.00 target price on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Finally, UBS Group increased their price target on Maplight Therapeutics from $48.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Four analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Maplight Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $34.42.
Get Our Latest Report on Maplight Therapeutics
Maplight Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Featured Articles
- Five stocks we like better than Maplight Therapeutics
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
